This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this book Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Czubryt, M. P. Articles by Olson, E. N. Search for Related Content PubMed PubMed Citation Articles by Czubryt, M. P. Articles by Olson, E. N.

Balancing Contractility and Energy Production: The Role of Myocyte Enhancer Factor 2 (MEF2) in Cardiac Hypertrophy

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9148

Cardiac hypertrophy — that is, enlargement of the heart resulting from increased myocyte size — is observed with many forms of human heart disease. It may arise secondary to an insult, such as infarct or chronic hypertension, or may occur as a consequence of a genetic defect, such as in hypertrophic cardiomyopathy. Traditionally, it has been widely believed that hypertrophy occurred as an adaptive response to normalize increased wall stress due to disease. Recently, however, it has been observed that while hypertrophy initially appears to improve the function of the heart following insult, over time, it frequently leads to a decompensated state, characterized by fibrosis and chamber dilation, resulting in overt heart failure. Hypertrophy also occurs during fetal development, immediately after birth, and in trained athletes; however, it does not lead to decompensation in these states. Experiments over the last 15 years have implicated similar signaling pathways in both pathological and physiological hypertrophic responses. Recently, important differences have been demonstrated that might hold the key to the development of effective new treatments for human diseases. This chapter focuses on how these hypertrophic responses differ from one another phenotypically and discusses how inefficient or impaired energy metabolism in the heart may contribute to the development of pathological responses. We also discuss recent evidence that the myocyte enhancer factor 2 (MEF2) transcription factor family, which previously has been shown to be important in cardiac development and hypertrophy, may have a role in regulation of cardiac energy metabolism.

This article has been cited by other articles:

				B. Feng, S. Chen, J. Chiu, B. George, and S. Chakrabarti Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1119 - E1126. [Abstract] [Full Text] [PDF]

				H.-T. Huang, O. M. Brand, M. Mathew, C. Ignatiou, E. P. Ewen, S. A. Mccalmon, and F. J. Naya Myomaxin Is a Novel Transcriptional Target of MEF2A That Encodes a Xin-related {alpha}-Actinin-interacting Protein J. Biol. Chem., December 22, 2006; 281(51): 39370 - 39379. [Abstract] [Full Text] [PDF]

				D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, H.-J. Tsai, I.-H. Kim, D. Tuteja, R. K. P. Mateo, A. Singapuri, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors PNAS, December 5, 2006; 103(49): 18733 - 18738. [Abstract] [Full Text] [PDF]

				T. P. Maddatu, S. M. Garvey, D. G. Schroeder, W. Zhang, S.-Y. Kim, A. I. Nicholson, C. J. Davis, and G. A. Cox Dilated cardiomyopathy in the nmd mouse: transgenic rescue and QTLs that improve cardiac function and survival Hum. Mol. Genet., November 1, 2005; 14(21): 3179 - 3189. [Abstract] [Full Text] [PDF]

				K. Baar New dimensions in tissue engineering: possible models for human physiology Exp Physiol, November 1, 2005; 90(6): 799 - 806. [Abstract] [Full Text] [PDF]

				B. Zhu, B. Ramachandran, and T. Gulick Alternative Pre-mRNA Splicing Governs Expression of a Conserved Acidic Transactivation Domain in Myocyte Enhancer Factor 2 Factors of Striated Muscle and Brain J. Biol. Chem., August 5, 2005; 280(31): 28749 - 28760. [Abstract] [Full Text] [PDF]